Previous 10 | Next 10 |
The shares of Kymera Therapeutics (NASDAQ:KYMR) have reached a 52-week low after the clinical-stage biotech reported a sharp revenue miss and provided a clinical update that could potentially delay its Phase 1 program for KT-474 targeted at immunology-inflammation diseases. KT-474 is currentl...
Gainers: Sonoma Pharmaceuticals (SNOA) +42%. XORTX Therapeutics (XRTX) +18%. Retractable Technologies (RVP) +14%. Catalent (CTLT) +12%. Field Trip Health (FTRP) +5%. Losers: Spero Therapeutics (SPRO) -61%. Semler Scientific (SMLR) -23%. Galmed Pharmaceu...
Kymera Therapeutics press release (NASDAQ:KYMR): Q1 GAAP EPS of -$0.71 misses by $0.05. Revenue of $9.62M (-48.6% Y/Y) misses by $9.04M. For further details see: Kymera Therapeutics GAAP EPS of -$0.71 misses by $0.05, revenue of $9.62M misses by $9.04M
IRAK4 degrader KT-474 Phase 1 patient cohort amended to extend dosing from 14 to 28 days, enabling inclusion of exploratory clinical efficacy endpoints and extended safety monitoring Clinical trials initiated for STAT3 (KT-333) and IRAKIMiD (KT-413) oncology programs P...
WATERTOWN, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will report first qua...
MDM2 degradation demonstrated differentiated biological activity and superior cell killing compared to small molecule inhibition in p53 wild-type tumors and led to tumor regressions in xenograft models of ALL and AML KT-253 is a highly potent and selective heterobifunctional MDM...
Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...
WATERTOWN, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will participate in t...
Shares of protein degradation biotech Kymera Therapeutics, Inc. (KYMR) are down some 40% from their January 3rd, 2022 close on little news, as the entire space has come under pressure. The reality of no revenue until at least 2026 has begun to set in despite its potentially paradigm-c...
Kymera Therapeutics press release (NASDAQ:KYMR): Q4 GAAP EPS of -$0.66 misses by $0.09. Revenue of $15.27M (+19.3% Y/Y) misses by $6.04M. For further details see: Kymera Therapeutics GAAP EPS of -$0.66 misses by $0.09, revenue of $15.27M misses by $6.04M
News, Short Squeeze, Breakout and More Instantly...
Kymera Therapeutics Inc. Company Name:
KYMR Stock Symbol:
NASDAQ Market:
Kymera Therapeutics Inc. Website:
2024-07-12 19:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-09 13:30:00 ET Shares of Kymera Therapeutics (NASDAQ: KYMR) were soaring 18.4% higher as of 11:28 a.m. ET on Tuesday. The big jump came after the clinical-stage biopharmaceutical company announced on Monday that its partner, Sanofi , plans to expand the ongoing phase 2 s...
WATERTOWN, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in a fireside ...